Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 11;11(1):e0143176.
doi: 10.1371/journal.pone.0143176. eCollection 2016.

Involving a Citizens' Jury in Decisions on Individual Screening for Prostate Cancer

Collaborators, Affiliations

Involving a Citizens' Jury in Decisions on Individual Screening for Prostate Cancer

Paola Mosconi et al. PLoS One. .

Abstract

Aims: Most public health agencies and learned societies agree that the prostate-specific antigen (PSA) test in asymptomatic men should not be recommended, on account of its potential for harm. Yet PSA is still widely used as a screening test and is not being abandoned. This remains a significant public health issue, and citizens' engagement is needed. This study was designed to produce a deliberation on the PSA screening test by a citizens' jury.

Methods: Fifteen citizens were selected and balanced for sex, age, and education. They received an information booklet and participated in a two-day meeting with experts to reach a deliberation on the question "Should the National Health Service discourage or recommend PSA as an individual screening test for prostate cancer in men 55-69 years old?". A facilitator ran the jurors' discussion.

Results: All except three of the jurors decided that the National Health Service should discourage the use of PSA as an individual screening test for prostate cancer in 55-69 year-old men. The jury was particularly convinced by the uncertainty of the test outcomes, the utility of the test, and its cost/benefit ratio. Before the meeting 60% of jurors would have recommended the test to a relative, and all the male jurors would have done so. After the meeting these percentages fell to 15% and 12%.

Conclusions: This experience confirms the feasibility and effectiveness of delegating to a group of citizens the responsibility to decide on public health issues on behalf of the community. Public health authorities should invest in information campaigns aimed at the public and in educational initiatives for physicians. This also provided an opportunity to disseminate information on screening, over-diagnosis, and over-treatment.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have the following interests. Roberto Satolli is employed by Agenzia di Editoria Scientifica Zadig. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

References

    1. Globocan. Available: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 12 March 2015.
    1. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2013; Issue 1 Art. No.: CD004720 10.1002/14651858.CD004720.pub3 - DOI - PMC - PubMed
    1. Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. for the ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320–1328. - PubMed
    1. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. PLCO Project Team. Mortality Results from a Randomized Prostate-Cancer Screening Trial. N Engl J Med 2009; 360:1310–1319. 10.1056/NEJMoa0810696 - DOI - PMC - PubMed
    1. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and metanalysis of randomized controlled trials. BMJ 2010; 341:c4543 10.1136/bmj.c4543 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances